NCT05492201View on ClinicalTrials.gov

A Study of LY3873862 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

84

Participants

Timeline

Start Date

August 11, 2022

Primary Completion Date

April 29, 2025

Study Completion Date

April 29, 2025

Conditions

Healthy

Interventions

DRUG

LY3873862

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research, London

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY